Holen Sie sich die Stockscreener-App
3.90
0.26%
0.010
Schlusskurs vom Vortag:
$3.89
Offen:
$3.89
24-Stunden-Volumen:
1.13M
Relative Volume:
0.33
Marktkapitalisierung:
$660.80M
Einnahmen:
$101.21M
Nettoeinkommen (Verlust:
$-569.00K
KGV:
-195.00
EPS:
-0.02
Netto-Cashflow:
$-56.88M
1W Leistung:
-2.50%
1M Leistung:
-6.92%
6M Leistung:
+44.44%
1J Leistung:
+222.31%
1-Tages-Spanne:
$3.78
$3.935
1-Wochen-Bereich:
$3.78
$4.1985
52-Wochen-Spanne:
$0.40
$4.62
Cytomx Therapeutics Inc Stock (CTMX) Company Profile
Firmenname
Cytomx Therapeutics Inc
Sektor
Branche
Telefon
650.515.3185
Adresse
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Vergleichen Sie CTMX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CTMX
Cytomx Therapeutics Inc
|
3.90 | 659.10M | 101.21M | -569.00K | -56.88M | -0.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.64 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.21 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.11 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-09-17 | Fortgesetzt | Barclays | Overweight |
| 2025-07-31 | Eingeleitet | Oppenheimer | Outperform |
| 2025-05-15 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-04-14 | Fortgesetzt | Piper Sandler | Overweight |
| 2024-05-28 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-05-09 | Hochstufung | Wedbush | Neutral → Outperform |
| 2024-05-06 | Hochstufung | Jefferies | Hold → Buy |
| 2024-04-22 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2022-11-14 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-07-07 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-07 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-07-07 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-07-07 | Herabstufung | Wedbush | Outperform → Neutral |
| 2022-06-24 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-01-18 | Hochstufung | Barclays | Underweight → Overweight |
| 2021-11-15 | Eingeleitet | BTIG Research | Buy |
| 2021-05-28 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2021-03-29 | Eingeleitet | JP Morgan | Overweight |
| 2021-03-23 | Hochstufung | Jefferies | Hold → Buy |
| 2020-09-22 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-06-01 | Herabstufung | Jefferies | Buy → Hold |
| 2020-05-14 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-24 | Hochstufung | Wedbush | Neutral → Outperform |
| 2020-03-04 | Eingeleitet | Barclays | Equal Weight |
| 2019-11-20 | Eingeleitet | Guggenheim | Buy |
| 2019-11-11 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-06-13 | Eingeleitet | Mizuho | Buy |
| 2019-05-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-03-11 | Eingeleitet | Barclays | Overweight |
| 2018-11-26 | Eingeleitet | Piper Jaffray | Overweight |
| 2018-10-15 | Eingeleitet | Goldman | Neutral |
| 2018-09-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-06-01 | Eingeleitet | SunTrust | Buy |
| 2018-01-05 | Eingeleitet | Citigroup | Buy |
| 2017-09-08 | Eingeleitet | Wedbush | Outperform |
| 2017-03-27 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-03-02 | Eingeleitet | Instinet | Buy |
| 2017-01-03 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2015-11-02 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Cytomx Therapeutics Inc Aktie (CTMX) Neueste Nachrichten
Can CytomX Therapeutics Stock Recover If Markets Fall? - Trefis
What analysts say about CytomX Therapeutics Inc stockVolume Weighted Average Price & Explosive Profit Potential - earlytimes.in
With CytomX Therapeutics Stock Sliding, Have You Assessed The Risk? - Trefis
What Analysts Think Is Changing the CytomX Therapeutics Story After Recent Cancer Developments - Yahoo Finance
CytomX Therapeutics stock maintains Buy rating at H.C. Wainwright ahead of key data By Investing.com - Investing.com South Africa
CytomX Therapeutics stock maintains Buy rating at H.C. Wainwright ahead of key data - Investing.com UK
Is CytomX Therapeutics Inc. stock a contrarian buyJuly 2025 PostEarnings & Technical Confirmation Alerts - Newser
Will CytomX Therapeutics Inc. stock beat EPS estimatesMarket Performance Report & Reliable Breakout Forecasts - Newser
Is CytomX Therapeutics Inc. (6C1) stock suitable for passive index funds2025 Earnings Surprises & Safe Entry Momentum Tips - Newser
Why CytomX Therapeutics Inc. (6C1) stock is listed among top recommendationsTrade Entry Report & High Accuracy Trade Alerts - Newser
Is CytomX Therapeutics Inc. (6C1) stock attractive post correctionProduct Launch & Real-Time Stock Movement Alerts - Newser
Published on: 2025-12-04 14:11:00 - Newser
Will CytomX Therapeutics Inc. (6C1) stock sustain dividend payoutsJuly 2025 Sector Moves & Verified Short-Term Plans - Newser
Would You Still Hold CytomX Therapeutics Stock If It Fell Another 30%? - Trefis
CytomX Therapeutics (NASDAQ:CTMX) Trading Down 6.5%What's Next? - MarketBeat
Is CytomX Therapeutics Inc. (6C1) stock ideal for retirement investorsJuly 2025 Patterns & Fast Gain Stock Trading Tips - Newser
What insider purchases suggest about CytomX Therapeutics Inc. (6C1) stockFed Meeting & Fast Gain Stock Trading Tips - Newser
Is CytomX Therapeutics Inc. (6C1) stock a buy on weaknessQuarterly Trade Summary & Fast Entry High Yield Tips - Newser
Will CytomX Therapeutics Inc. (6C1) stock outperform Dow JonesSell Signal & High Return Stock Watch Alerts - Newser
How CytomX Therapeutics Inc. (6C1) stock reacts to weak economy2025 Price Targets & Entry Point Confirmation Alerts - Newser
Portfolio Shifts: Is CytomX Therapeutics Inc 6C1 stock undervalued by metricsWeekly Loss Report & Daily Technical Stock Forecast Reports - BỘ NỘI VỤ
Will CytomX Therapeutics Inc. (6C1) stock benefit from infrastructure billWeekly Volume Report & High Conviction Buy Zone Picks - Newser
Why CytomX Therapeutics Inc. (6C1) stock is a strong buy callQuarterly Profit Report & Daily Market Momentum Tracking - Newser
What analyst consensus says on CytomX Therapeutics Inc. stockMarket Performance Summary & Risk Managed Trade Strategies - Newser
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
CapEx per share of CytomX Therapeutics, Inc. – DUS:6C1 - TradingView
Revenue per share of CytomX Therapeutics, Inc. – DUS:6C1 - TradingView
Operating cash flow per share of CytomX Therapeutics, Inc. – DUS:6C1 - TradingView
Is CytomX Therapeutics Inc. stock a top pick in earnings seasonJuly 2025 Decliners & Real-Time Volume Analysis Alerts - BỘ NỘI VỤ
Franklin Resources Inc. Invests $13.10 Million in CytomX Therapeutics, Inc. $CTMX - MarketBeat
CytomX Therapeutics jumps 54% after Q1 beat, prices $100M offering - MSN
CTMX (CytomX Therapeutics) Other Income (Minority Interest) : $0.0 Mil (TTM As of Sep. 2025) - GuruFocus
CX-2051 Momentum and An Expanding Oncology Pipeline Strengthen CytomX Therapeutics’ (CTMX) Investment Case - Insider Monkey
Will CytomX Therapeutics Inc. stock recover faster than peers2025 Historical Comparison & Fast Entry High Yield Tips - BỘ NỘI VỤ
Is CytomX Therapeutics Inc. (6C1) stock attractive for dividend growthJuly 2025 Snapshot & Technical Pattern Based Buy Signals - moha.gov.vn
Can CytomX Therapeutics Inc. stock sustain free cash flow growth2025 Price Targets & Weekly Watchlist for Hot Stocks - BỘ NỘI VỤ
Will CytomX Therapeutics Inc. stock split attract more investors2025 Key Lessons & Long-Term Growth Portfolio Plans - BỘ NỘI VỤ
ON Partners Recruits Chief Business Officer for CytomX Therapeutics - Hunt Scanlon Media
CytomX Therapeutics to Present at Upcoming December Investor Conferences - The Manila Times
CytomX Therapeutics (NASDAQ: CTMX) joins Evercore, Piper Sandler healthcare investor conferences in December - Stock Titan
Why Analysts Say the CytomX Story Is Evolving After Recent Clinical Momentum and Price Target Hike - Yahoo Finance
CytomX Therapeutics (CTMX) Price Target Increased by 15.12% to 7.21 - MSN
CytomX Therapeutics Inc Stock Analysis and ForecastVolume Profile Analysis & Superior Portfolio Investment - earlytimes.in
Will CytomX Therapeutics Inc. stock deliver consistent dividendsTrade Entry Report & Expert Curated Trade Setup Alerts - newser.com
Will CytomX Therapeutics Inc. stock see insider buyingEarnings Overview Summary & Low Risk High Reward Ideas - newser.com
Why CytomX Therapeutics Inc. (6C1) stock gets analyst attentionExit Point & High Accuracy Buy Signal Tips - newser.com
CTMX (CytomX Therapeutics) Price-to-Operating-Cash-Flow : (As of Nov. 20, 2025) - GuruFocus
CytomX at Jefferies Conference: Promising Cancer Treatment Insights By Investing.com - Investing.com Canada
CytomX Therapeutics stock holds Overweight rating at Cantor Fitzgerald By Investing.com - Investing.com Canada
Finanzdaten der Cytomx Therapeutics Inc-Aktie (CTMX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):